Absci (ABSI) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Absci (ABSI) has outperformed Zenas BioPharma (ZBIO) over the past year, gaining 146.5% versus a gain of 35.2%. Zenas BioPharma is the larger company by market cap ($1.84 billion vs $1.58 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | ZBIO |
|---|---|---|
| Share price | $9.22 | $28.18 |
| Market cap | $1.58B | $1.84B |
| 1-day change | -10.22% | +4.60% |
| YTD return | +164.18% | -22.39% |
| 1-year return | +146.52% | +35.16% |
| 5-year return | -13.26% | — |
| EPS (TTM) | $-0.79 | $-9.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $44.60 |
| 52-week low | $2.24 | $13.50 |
| Distance from 52-week high | -23.52% | -36.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +56.18% | +69.91% |
| Average volume | 3.46M | 739.60K |
| Shares outstanding | 171.61M | 65.18M |
| Employees | 140 | 167 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed ZBIO by 111.4 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Healthcare · Biotechnology · 140 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Healthcare · Biotechnology · 167 employees
ABSI vs ZBIO FAQ
Which is bigger, Absci or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.84B compared with $1.58B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or ZBIO?
ABSI returned +146.52% over the past 12 months, compared with +35.16% for ZBIO (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.